- Home
- BIGC vs RGNX Comparison
BIGC vs RGNX Comparison
Compare BIGC & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIGC
- RGNX
- Stock Information
- Founded
- BIGC 2009
- RGNX 2008
- Country
- BIGC United States
- RGNX United States
- Employees
- BIGC N/A
- RGNX N/A
- Industry
- BIGC Computer Software: Prepackaged Software
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BIGC Technology
- RGNX Health Care
- Exchange
- BIGC Nasdaq
- RGNX Nasdaq
- Market Cap
- BIGC 386.9M
- RGNX 387.0M
- IPO Year
- BIGC 2020
- RGNX 2015
- Fundamental
- Price
- BIGC $5.19
- RGNX $8.74
- Analyst Decision
- BIGC Hold
- RGNX Strong Buy
- Analyst Count
- BIGC 7
- RGNX 8
- Target Price
- BIGC $7.64
- RGNX $31.75
- AVG Volume (30 Days)
- BIGC 771.6K
- RGNX 1.0M
- Earning Date
- BIGC 07-31-2025
- RGNX 07-31-2025
- Dividend Yield
- BIGC N/A
- RGNX N/A
- EPS Growth
- BIGC N/A
- RGNX N/A
- EPS
- BIGC N/A
- RGNX N/A
- Revenue
- BIGC $334,937,000.00
- RGNX $156,718,000.00
- Revenue This Year
- BIGC $5.06
- RGNX $327.08
- Revenue Next Year
- BIGC $5.20
- RGNX N/A
- P/E Ratio
- BIGC N/A
- RGNX N/A
- Revenue Growth
- BIGC 5.33
- RGNX 80.70
- 52 Week Low
- BIGC $4.73
- RGNX $5.04
- 52 Week High
- BIGC $8.50
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- BIGC 53.33
- RGNX 49.54
- Support Level
- BIGC $4.92
- RGNX $7.91
- Resistance Level
- BIGC $5.24
- RGNX $8.99
- Average True Range (ATR)
- BIGC 0.19
- RGNX 0.65
- MACD
- BIGC 0.03
- RGNX -0.05
- Stochastic Oscillator
- BIGC 76.47
- RGNX 37.70
About BIGC BigCommerce Holdings Inc. Series 1
BigCommerce Holdings Inc is engaged in offering Software-as-a-service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which majority of revenue is generated from Americas-U.S.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.